Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.

Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer. Gynecol Oncol. 2021 11; 163(2):254-261.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Doxorubicin
Drug Resistance, Neoplasm
Female
Humans
Intercellular Signaling Peptides and Proteins
Middle Aged
Neoplasm Recurrence, Local
Ovarian Neoplasms
Paclitaxel
Polyethylene Glycols
Proto-Oncogene Proteins
Receptor Protein-Tyrosine Kinases
Recombinant Fusion Proteins

authors with profiles

ROBERT COLEMAN